Epigallo Catechin Gallate (EGCG) and Sorafenib: A Better Cytoprotective Agent in Diethyl Nitrosamine (DEN) Induced Liver Cancer – Anin Vivo Study

Introduction: Carcinoma of the liver is the most frequently noticed malignant neoplasm of the liver and it occupies the third position in cancer-related deaths. Epicatechin-3-gallate, Epigallocatechin-3-gallate, abbreviated as EGCG, constitutes about 50-75% of the catechins. Administration of EGCG inhibits the proliferation of cancerous cells and encourages cell death (apoptosis). Sorafenib is an oral multikinase inhibitor that exerts its inhibitory effects on tumours through angiogenesis inhibition. So, the present study was undertaken to analyse the beneficial effects of naturally occurring agents, EGCG and sorafenib, on carcinoma of the liver. Materials and Methods: 40 adult male Wistar albino rats were procured and divided into five equal groups. Control animals were in Group 1 and negative controls were in Group 2 Sorafenib treatment was given to Group 3 and EGCG alone was given to Group 4 Group 5 received both sorafenib and EGCG. Results: We have found that the combined treatment group of EGCG and sorafenib had low levels of AFP, increased levels of mitochondrial enzymes, Phase II enzymes and showed a decrease in enzymes of Phase I and a fall in glycoprotein components level. Conclusion: Epigallocatechin-gallate (EGCG) when given with sorafenib has shown enhanced cytoprotective effects. How to cite this article:Neelamegam U, Suganthi V, Muthuvel R. Epigallo Catechin Gallate (EGCG) and Sorafenib: A Better Cytoprotective Agent in Diethyl Nitrosamine (DEN) Induced Liver Cancer – An in Vivo Study. Chettinad Health City Med J. 2023;12(2):63-70. DOI: https://doi.org/10.24321/2278.2044.202329